Observational studyMedicine2025
The clinical value of lymph-node dissection in hepatitis B virus-associated intrahepatic cholangiocarcinoma.
Observational study in Medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatitis B virus-associated intrahepatic cholangiocarcinoma (HBV-ICC) exhibits distinct clinicopathological characteristics, and the role of lymph-node dissection (LND) in its management remains contentious. This study aims to evaluate the clinical value of LND in HBV-ICC. Clinicopathological data of 76 HBV-ICC patients treated at Pingxiang People's Hospital between 2015 and 2020 were analyzed. The cohort comprised 41 patients who underwent LND (LND[+] group) and 35 patients who did not (LND[-] group). Clinicopathological characteristics, perioperative outcomes, and survival were subjected to statistical analysis. The cohort had 1-, 2-, and 5- year overall survival (OS) rates of 85.5%, 27.6%, and 13.2%. The LND(+) group had significantly higher postoperative complications than the LND(-) group (P < .05). OS and postoperative recurrence rates did not significantly differ between the 2 groups (P = .71 and P = .44). Multivariate analysis showed that independent risk factors for poor prognosis after ICC resection included resection margin < 1cm (HR = 3.97 [2.11-7.48], P < .05), poor tumor differentiation (HR = 0.43 [0.19-0.95], P < .05), microvascular invasion (HR = 1.92 [0.98-3.78], P < .05), and nonanatomic hepatectomy (HR = 2.07 [1.13-3.81], P < .05). Resection margin, tumor differentiation, microvascular invasion, and anatomic hepatectomy were identified as independent prognostic factors in HBV-ICC. LND did not improve patient outcomes while potentially increasing complication risks, thus not recommended.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.